Graffinity Enters into Drug Discovery Research Collaboration with Genentech

16-Oct-2009 - Germany

Graffinity Pharmaceuticals GmbH announced that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group. With this collaboration Genentech will gain access to Graffinity’s proprietary, fragment-based drug discovery technology.

Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...